CH Biomedical, Inc. was founded in 2008 by a team of scientific and technological experts with overseas experience with the goal to improve survival and quality of life for end-stage heart failure patients. The headquarters is located in Suzhou Industrial Park while the wholly owned subsidiary, CH Biomedical USA, Inc., is in LA, California. CH Biomedical focuses on research and development of the state-of-the-art ventricular assist device (VAD), bringing benefits to the wide patient population with end-stage heart failure.more
VAD is a mechatronics device used to provide support to the heart pumping blood and maintain human blood circulation. Its core component is a blood pump, which draws blood from the heart, increases the pressure, and then pumps it to aorta. After more than 50 years’ research in the United States and other developed countries, VAD technology has been approved by FDA as an alternative treatment for severe heart failure in replacement of permanent heart transplant. So far, nearly 100,000 cases of clinical use have shown that VAD can help patients with heart failure to significantly improve quality of life and longevity with a possibility of cardiac rehabilitation. The VAD industry has developed into an important segment of the cardiovascular medical device industry.more
We are a diverse and innovative team. We respect and value every employee. We believe that each employee's uniqueness in wisdom, perspective and talent will contribute to the team’s development by leaps and bounds.